ALDX
Aldeyra Therapeutics, Inc.
Price Chart
Latest Quote
$5.43
Current Price| Previous Close | $5.36 |
| Open | $5.32 |
| Day High | $5.59 |
| Day Low | $5.25 |
| Volume | 347,419 |
Stock Information
| Shares Outstanding | 60.16M |
| Total Debt | $15.54M |
| Cash Equivalents | $75.30M |
| Net Income | $-43.19M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $326.68M |
| EPS (TTM) | $-0.73 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.22 |
| Debt to Earnings | -0.27 |
| Current Ratio | 5.59 |
| Quick Ratio | 5.44 |
| Return on Equity | -78.66% |
| Avg FCF Growth | 0.38% |
| FCF Yield | -13.23% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $5.43 | 356,000 |
| 2026-01-30 | $5.36 | 742,900 |
| 2026-01-29 | $5.32 | 525,400 |
| 2026-01-28 | $5.42 | 595,700 |
| 2026-01-27 | $5.54 | 865,300 |
| 2026-01-26 | $5.23 | 620,300 |
| 2026-01-23 | $5.19 | 1,256,100 |
| 2026-01-22 | $5.22 | 958,400 |
| 2026-01-21 | $4.99 | 1,192,900 |
| 2026-01-20 | $4.75 | 1,020,000 |
| 2026-01-16 | $4.63 | 1,634,900 |
| 2026-01-15 | $4.41 | 835,600 |
| 2026-01-14 | $4.24 | 593,900 |
| 2026-01-13 | $4.14 | 527,500 |
| 2026-01-12 | $4.13 | 617,500 |
| 2026-01-09 | $4.11 | 643,500 |
| 2026-01-08 | $4.18 | 548,700 |
| 2026-01-07 | $4.16 | 883,400 |
| 2026-01-06 | $4.06 | 1,118,400 |
| 2026-01-05 | $4.24 | 1,213,500 |
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
đ° Latest News
ATA Creativity Global Among 3 Promising Penny Stocks
Simply Wall St. âĸ 2026-01-20T12:05:20Z
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist
Simply Wall St. âĸ 2025-12-22T12:05:06Z
Aldeyra Says FDA Extends Action Date for Potential Dry Eye Disease Treatment; Shares Down Pre-Bell
MT Newswires âĸ 2025-12-16T11:10:00ZAldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures
Simply Wall St. âĸ 2025-12-08T10:49:27Z
High Growth Tech Stocks In The US Market November 2025
Simply Wall St. âĸ 2025-11-06T17:38:15Z
Exploring 3 High Growth Tech Stocks In The US Market
Simply Wall St. âĸ 2025-11-06T11:38:13Z
High Growth Tech Opportunities in the US Market
Simply Wall St. âĸ 2025-11-05T11:38:14Z
High Growth Tech Stocks In US With Promising Potential
Simply Wall St. âĸ 2025-10-31T17:38:10Z
High Growth Tech Stocks In The US Market With Promising Potential
Simply Wall St. âĸ 2025-10-31T11:38:17Z
High Growth Tech Stocks To Watch In US This October 2025
Simply Wall St. âĸ 2025-10-30T11:38:13Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $1,926,241 | $2,071,435 | $1,694,098 | $1,742,101 |
| Total Expenses | $60,117,032 | $42,794,083 | $62,679,987 | $56,219,536 |
| Net Non Operating Interest Income Expense | $4,265,588 | $5,251,573 | $655,351 | $-1,556,738 |
| Interest Expense Non Operating | $1,926,241 | $2,071,435 | $1,694,098 | $1,742,101 |
| Operating Expense | $60,117,032 | $42,794,083 | $62,679,987 | $56,219,536 |
| General And Administrative Expense | $11,892,239 | $13,335,364 | $15,373,921 | $11,283,004 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Net Interest Income | $4,265,588 | $5,251,573 | $655,351 | $-1,556,738 |
| Interest Income | $6,191,829 | $7,323,008 | $2,349,449 | $185,363 |
| Normalized Income | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Net Income From Continuing And Discontinued Operation | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Total Operating Income As Reported | $-60,117,032 | $-42,794,083 | $-62,679,987 | $-56,219,536 |
| Net Income Common Stockholders | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Net Income | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Net Income Including Noncontrolling Interests | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Net Income Continuous Operations | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Pretax Income | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Interest Income Non Operating | $6,191,829 | $7,323,008 | $2,349,449 | $185,363 |
| Operating Income | $-60,117,032 | $-42,794,083 | $-62,679,987 | $-56,219,536 |
| Special Income Charges | - | - | - | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.94 | $-0.64 | $-1.06 | $-1.07 |
| Basic EPS | $-0.94 | $-0.64 | $-1.06 | $-1.07 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-53,675,580 | $-35,208,295 | $-60,071,831 | $-55,769,993 |
| Reconciled Depreciation | $249,623 | $262,780 | $258,707 | $264,180 |
| EBITDA (Bullshit earnings) | $-53,675,580 | $-35,208,295 | $-60,071,831 | $-55,769,993 |
| EBIT | $-53,925,203 | $-35,471,075 | $-60,330,538 | $-56,034,173 |
| Diluted Average Shares | $59,484,794 | $58,943,205 | $58,405,897 | $54,042,103 |
| Basic Average Shares | $59,484,794 | $58,943,205 | $58,405,897 | $54,042,103 |
| Diluted NI Availto Com Stockholders | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Research And Development | $48,224,793 | $29,458,719 | $47,306,066 | $44,936,532 |
| Selling General And Administration | $11,892,239 | $13,335,364 | $15,373,921 | $11,283,004 |
| Other Gand A | $11,892,239 | $13,335,364 | $15,373,921 | $11,283,004 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Tax Provision | - | - | - | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $71,004,871 | $119,795,030 | $151,008,029 | $205,735,523 |
| Total Assets | $104,606,694 | $148,326,911 | $181,291,657 | $233,137,120 |
| Total Non Current Assets | $534,216 | $516,578 | $268,544 | $384,350 |
| Non Current Deferred Assets | $267,261 | $0 | - | - |
| Current Assets | $104,072,478 | $147,810,333 | $181,023,113 | $232,752,770 |
| Other Current Assets | $301,152 | $183,146 | $442,721 | $93,456 |
| Current Deferred Assets | $2,211,963 | $4,463,783 | $2,605,252 | $2,404,145 |
| Prepaid Assets | $408,091 | $340,388 | $432,230 | $435,410 |
| Cash Cash Equivalents And Short Term Investments | $101,151,272 | $142,823,016 | $174,300,884 | $229,790,989 |
| Cash And Cash Equivalents | $54,527,092 | $142,823,016 | $144,419,364 | $229,790,989 |
| Cash Equivalents | $30,793,079 | $14,312,565 | $9,268,283 | $129,426,466 |
| Cash Financial | $23,734,013 | $128,510,451 | $135,151,081 | $100,364,523 |
| Receivables | - | $0 | $3,242,026 | $28,770 |
| Other Receivables | - | - | $3,242,026 | $28,770 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $15,303,003 | $15,657,360 | $16,084,118 | $15,858,542 |
| Long Term Debt And Capital Lease Obligation | $15,000,000 | $271,631 | $14,923,090 | $15,628,935 |
| Long Term Debt | $15,000,000 | - | $14,923,090 | $15,503,703 |
| Current Debt And Capital Lease Obligation | $303,003 | $15,385,729 | $1,161,028 | $229,607 |
| Current Debt | $31,372 | $15,146,546 | $911,763 | - |
| Other Current Borrowings | $31,372 | $15,146,546 | $911,763 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $33,601,823 | $28,531,881 | $30,283,628 | $27,401,597 |
| Total Non Current Liabilities Net Minority Interest | $15,000,000 | $6,271,631 | $14,923,090 | $15,628,935 |
| Non Current Deferred Liabilities | $0 | $6,000,000 | $0 | - |
| Current Liabilities | $18,601,823 | $22,260,250 | $15,360,538 | $11,772,662 |
| Current Deferred Liabilities | $6,000,000 | $0 | - | - |
| Payables And Accrued Expenses | $7,965,604 | $3,786,584 | $10,377,606 | $10,030,170 |
| Payables | $180,453 | $1,338,057 | $133,625 | $1,019,702 |
| Accounts Payable | $180,453 | $1,338,057 | $133,625 | $1,019,702 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $71,004,871 | $119,795,030 | $151,008,029 | $205,735,523 |
| Total Equity Gross Minority Interest | $71,004,871 | $119,795,030 | $151,008,029 | $205,735,523 |
| Stockholders Equity | $71,004,871 | $119,795,030 | $151,008,029 | $205,735,523 |
| Gains Losses Not Affecting Retained Earnings | $37,442 | $0 | $-103,938 | $0 |
| Other Equity Adjustments | $37,442 | - | $-103,938 | - |
| Retained Earnings | $-450,110,592 | $-394,259,148 | $-356,716,638 | $-294,692,002 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $59,648,278 | $59,195,951 | $58,560,078 | $58,081,215 |
| Share Issued | $59,648,278 | $59,195,951 | $58,560,078 | $58,081,215 |
| Tangible Book Value | $71,004,871 | $119,795,030 | $151,008,029 | $205,735,523 |
| Invested Capital | $86,036,243 | $134,941,576 | $166,842,882 | $221,239,226 |
| Working Capital | $85,470,655 | $125,550,083 | $165,662,575 | $220,980,108 |
| Capital Lease Obligations | $271,631 | $510,814 | $249,265 | $354,839 |
| Total Capitalization | $86,004,871 | $119,795,030 | $165,931,119 | $221,239,226 |
| Additional Paid In Capital | $521,018,373 | $513,994,982 | $507,770,045 | $500,369,444 |
| Capital Stock | $59,648 | $59,196 | $58,560 | $58,081 |
| Common Stock | $59,648 | $59,196 | $58,560 | $58,081 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $6,000,000 | $0 | - |
| Long Term Capital Lease Obligation | $0 | $271,631 | $0 | $125,232 |
| Current Deferred Revenue | $6,000,000 | $0 | - | - |
| Current Capital Lease Obligation | $271,631 | $239,183 | $249,265 | $229,607 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,333,216 | $3,087,937 | $3,821,904 | $1,512,885 |
| Current Accrued Expenses | $7,785,151 | $2,448,527 | $10,243,981 | $9,010,468 |
| Net PPE | $266,955 | $516,578 | $268,544 | $384,350 |
| Gross PPE | $266,955 | $516,578 | $268,544 | $384,350 |
| Other Properties | $266,955 | $516,578 | $268,544 | $384,350 |
| Other Short Term Investments | $46,624,180 | $0 | $29,881,520 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-43,208,747 | $-30,326,128 | $-56,653,504 | $-42,563,713 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-43,208,747 | $-30,326,128 | $-56,637,187 | $-42,555,907 |
| Cash Flow From Continuing Operating Activities | $-43,208,747 | $-30,326,128 | $-56,637,187 | $-42,555,907 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Investing Cash Flow | $-44,915,755 | $30,000,000 | $-29,954,530 | $-7,806 |
| Cash Flow From Continuing Investing Activities | $-44,915,755 | $30,000,000 | $-29,954,530 | $-7,806 |
| Capital Expenditure | - | - | $-16,317 | $-7,806 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $-171,422 | $-1,270,220 | $1,220,092 | $194,496,391 |
| Cash Flow From Continuing Financing Activities | $-171,422 | $-1,270,220 | $1,220,092 | $194,496,391 |
| Net Other Financing Charges | $-267,261 | $-532,951 | - | - |
| Issuance Of Capital Stock | - | - | $0 | $189,811,611 |
| Net Common Stock Issuance | - | - | $0 | $189,811,611 |
| Common Stock Issuance | - | - | $0 | $189,811,611 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-292,500 | $-1,042,500 | $0 | - |
| Interest Paid Supplemental Data | $1,753,792 | $1,702,188 | $1,338,542 | $1,337,083 |
| End Cash Position | $54,527,092 | $142,823,016 | $144,419,364 | $229,790,989 |
| Beginning Cash Position | $142,823,016 | $144,419,364 | $229,790,989 | $77,858,311 |
| Changes In Cash | $-88,295,924 | $-1,596,348 | $-85,371,625 | $151,932,678 |
| Proceeds From Stock Option Exercised | $388,339 | $305,231 | $1,220,092 | $4,684,780 |
| Net Issuance Payments Of Debt | $-292,500 | $-1,042,500 | $0 | - |
| Net Long Term Debt Issuance | $-292,500 | $-1,042,500 | $0 | - |
| Long Term Debt Payments | $-292,500 | $-1,042,500 | $0 | - |
| Net Investment Purchase And Sale | $-44,915,755 | $30,000,000 | $-29,938,213 | $0 |
| Sale Of Investment | $52,000,000 | $30,000,000 | $63,000,000 | $0 |
| Purchase Of Investment | $-96,915,755 | $0 | $-92,938,213 | $0 |
| Change In Working Capital | $5,913,232 | $861,180 | $-3,444,139 | $7,438,689 |
| Change In Payables And Accrued Expense | $3,847,121 | $-6,873,732 | $316,309 | $5,199,513 |
| Change In Accrued Expense | $5,004,725 | $-8,078,164 | $1,202,386 | $4,561,449 |
| Change In Payable | $-1,157,604 | $1,204,432 | $-886,077 | $638,064 |
| Change In Account Payable | $-1,157,604 | $1,204,432 | $-886,077 | $638,064 |
| Change In Prepaid Assets | $2,066,111 | $1,734,912 | $-3,760,448 | $2,239,176 |
| Other Non Cash Items | $177,326 | $354,193 | $331,150 | $409,471 |
| Stock Based Compensation | $7,973,499 | $5,752,771 | $8,288,976 | $7,108,027 |
| Amortization Of Securities | $-1,670,983 | $-14,542 | $-47,245 | $0 |
| Depreciation Amortization Depletion | $249,623 | $262,780 | $258,707 | $264,180 |
| Depreciation And Amortization | $249,623 | $262,780 | $258,707 | $264,180 |
| Net Income From Continuing Operations | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 |
| Net PPE Purchase And Sale | - | $0 | $-16,317 | $-7,806 |
| Purchase Of PPE | - | $0 | $-16,317 | $-7,806 |
| Change In Other Working Capital | - | $6,000,000 | - | - |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |